Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).
Marwan Fakih(City of Hope), Andrew Scott Paulson(Texas Oncology), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Matthias Herpers, Neelesh Sharma(Bayer (United States)), David Cosgrove(Compass Oncology), Joseph A. Fiorillo(Willamette Valley Cancer Institute and Research Center), Timothy K. Huyck(Nebraska Cancer Specialists), David Chang(The University of Texas MD Anderson Cancer Center), Lawrence Garbo(New York Oncology Hematology), Ying A. Wang(Bayer (United States)), Shruthi Ravimohan(Bristol-Myers Squibb (United States)), Von Potter(Bristol-Myers Squibb (United States)), David R. D’Adamo(Eisai (United States)), Sabine Coppieters(Bayer (Belgium)), Carolina S.V. Oliveira(Bayer (United States)), Timothy Larson(The US Oncology Network), Allen Lee Cohn(Rocky Mountain Cancer Centers), Johanna C. Bendell(Dana-Farber Cancer Institute)
Cited by 74
Related Papers
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2016|766
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2011|684